An integrated proteomic approach to identifying circulating biomarkers in high‐risk neuroblastoma and their potential in relapse monitoring

Further validation of these biomarkers may improve patients' outcomes by developing a simple blood test for the detection of relapse prior to the development of clinically evident disease. Understanding the role of these biomarkers in immune surveillance of neuroblastoma may also provide a new direction of therapeutic strategies.